NADAC acquisition cost data for ORILISSA 200 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
| 00074003956 | $18.11 | 2022-01-14 | Rx |
Generic: Elagolix Sodium | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $1.8M | 1,791 | 538 | $26.75 |
| 2020 | $3.0M | 2,795 | 663 | $29.25 |
| 2021 | $3.3M | 2,834 | 627 | $32.61 |
| 2022 | $3.7M | 2,869 | 620 | $35.43 |
| 2023 | $3.6M | 2,624 | 575 | $37.01 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $308.5K | 203 | 45 |
| Pennsylvania | $244.6K | 192 | 36 |
| California | $225.8K | 159 | 36 |
| Ohio | $203.7K | 173 | 33 |
| Texas | $166.4K | 121 | 36 |
| Florida | $165.2K | 108 | 29 |
| Louisiana | $132.9K | 86 | 19 |
| South Carolina | $132.5K | 105 | 17 |
| Maryland | $124.6K | 75 | 12 |
| North Carolina | $113.9K | 63 | 17 |
| Michigan | $113.2K | 59 | 18 |
| Missouri | $110.5K | 106 | 17 |
| Massachusetts | $96.7K | 76 | 16 |
| New Jersey | $95.8K | 74 | 13 |
| Minnesota | $94.0K | 68 | 12 |
| Connecticut | $92.5K | 56 | 12 |
| Alabama | $91.4K | 70 | 16 |
| Georgia | $90.8K | 66 | 17 |
| Kentucky | $87.3K | 74 | 17 |
| Virginia | $86.2K | 73 | 14 |
| Indiana | $73.4K | 55 | 12 |
| Tennessee | $73.0K | 62 | 11 |
| Washington | $67.6K | 49 | 12 |
| Illinois | $60.6K | 40 | 12 |
| Wisconsin | $56.3K | 45 | 13 |
| Kansas | $46.3K | 35 | N/A |
| Arkansas | $44.2K | 34 | N/A |
| New Hampshire | $41.5K | 29 | N/A |
| Arizona | $40.7K | 29 | N/A |
| Oklahoma | $40.1K | 30 | N/A |
| Colorado | $39.2K | 15 | N/A |
| Maine | $36.2K | 23 | N/A |
| Oregon | $33.4K | 27 | N/A |
| Idaho | $28.5K | 19 | N/A |
| Nebraska | $28.4K | 16 | N/A |
| Montana | $26.3K | 17 | N/A |
| Nevada | $24.3K | 19 | N/A |
| Alaska | $19.1K | 14 | N/A |
| Rhode Island | $18.0K | 11 | N/A |
| Puerto Rico | $14.9K | 13 | N/A |
| Iowa | $13.1K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.